Flexible, high-throughput recombinant antibody expression and ELISA screening designed for rapid AI model iteration.
The practical challenge is no longer sequence generation alone. It is converting large candidate sets into consistent, usable antibody material for experimental confirmation.
Internal teams may be optimized for selected leads, not for parallel expression and purification of tens or hundreds of newly designed antibodies.
Delivering every expressed clone directly into functional assays can increase reagent use, labor, and validation time.
Some teams require economical bulk expression, while others need pre-screened binders or rapid delivery for established internal assays.
Configure the service around your sequence volume, internal capabilities, screening strategy, and budget.
Core logic: Pricing is based on sequence count and antibody specifications for clear project planning.
Service upgrade: Optional target-binding ELISA screening is completed before final delivery.
Target clients: Teams with mature in-house validation systems that prioritize delivery efficiency and experimental control.
Submit your requirements to receive a free customized service recommendation and an additional 10% discount on your first service order.
Project requirements are defined upfront so expression scale, screening scope, and deliverables match the intended downstream application.
Confirm sequence count, antibody format, species, tags, and project objectives.
Select 4 mL, 10 mL, or 30 mL scale based on screening and assay needs.
Execute high-throughput recombinant antibody production in parallel.
Prepare purified antibody material and associated quality documentation.
Complete optional ELISA screening and deliver qualified project outputs.
The service is designed to support downstream binding confirmation, functional assays, candidate ranking, developability assessment, and model iteration.
For AI teams, experimentally qualified results can also serve as feedback data for sequence-ranking models, active-learning loops, and subsequent design cycles.
Suitable for AI-native discovery companies, biotechnology teams, CROs, and pharmaceutical research groups handling expanding candidate libraries.
Express ranked sequence candidates and generate physical material for experimental verification.
Compare broad candidate panels before committing resources to detailed functional characterization.
Produce engineered variants for binding comparison, specificity review, and iterative optimization.
Outsource high-volume expression while retaining binding and functional validation internally.
The service is designed for projects ranging from approximately 10 to 1,000 sequences. The appropriate workflow depends on antibody format, expression scale, project complexity, and screening requirements.
Standard project options include 4 mL, 10 mL, and 30 mL formats. The recommended volume should be selected according to the downstream assay and material requirements.
Yes. Target-binding ELISA can be added before delivery to help identify positive-binding clones and reduce the number of candidates entering downstream assays.
Yes. Expression-only service is suitable for customers with established internal binding, specificity, and functional assay platforms.
Please provide the approximate number of sequences, antibody format, preferred expression scale, target information, required screening scope, expected deliverables, and intended downstream application.
Yes. The modular structure can support successive design–build–test–learn cycles, subject to project specifications and production planning.
Tell us about your project. The CUSABIO technical team will prepare a customized high-throughput recombinant antibody expression plan based on your requirements.
